Josep Tabernero, MD, PhD, and Alexis A. Thompson, MD, MPH, are featured.
Josep Tabernero, MD, PhD, director of the Vall d'Hebron Institute of Oncology in Barcelona, Spain, began his 2-year term as president of the European Society for Medical Oncology on January 1. He is principal investigator on several phase I trials of targeted therapies, particularly EGFR inhibitors and IGFR–PI3K–AKT–mTOR pathway inhibitors, and aims to establish biomarkers of response and resistance to anticancer therapies. He also develops patient-derived xenograft models in mice to mimic patients' disease and leads research on the detection and sequencing of circulating free DNA. He serves on the editorial boards of multiple journals, including Cancer Discovery and Clinical Cancer Research.
Alexis A. Thompson, MD, MPH, began a 1-year term as president of the American Society of Hematology on December 12 at the organization's 2017 Annual Meeting in Atlanta, GA. She is the head of the hematology section of the Division of Hematology Oncology Transplantation at Ann and Robert H. Lurie Children's Hospital in Chicago, IL, and associate director of Equity and Minority Health at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, also in Chicago. Her major fields of interest include sickle cell disease, thalassemia, transfusional iron overload, and stem cell transplantation for pediatric patients.
For more news on cancer research, visit Cancer Discovery online at http://cancerdiscovery.aacrjournals.org/content/early/by/section.